Want to see HK:8156 full AI Analyst Report?

Sinopharm Tech Holdings Limited (8156) Price & Analysis

0 Followers

8156 Stock Chart & Stats

HK$0.22

HK$0.00(0.00%)

At close: Sep 30 4:00 PM EDT

HK$0.22

HK$0.00(0.00%)

Day’s Range― - ―

52-Week RangeHK$0.06 - HK$0.36

Previous CloseN/A

Volume194.40K

Average Volume (3M)2.62K

Market Cap

HK$137.51M

Enterprise ValueHK$173.64

Total Cash (Recent Filing)HK$5.62M

Total Debt (Recent Filing)HK$30.73M

Price to Earnings (P/E)―

Beta0.46

Next Earnings

Mar 04, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding633,693,050

10 Day Avg. Volume16

30 Day Avg. Volume2,618

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)-2.03

Price to Sales (P/S)2.07

P/FCF Ratio-23.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt ReductionDebt reduction versus prior years is a modest improvement in financial flexibility and may reduce future financing pressure. However, the benefit is limited because debt remains meaningful relative to assets and the company continues to have negative shareholders’ equity.

Losses Less Severe Than Earlier PeriodsThe company’s losses are less severe than in 2021–2022, showing some historical improvement in the depth of earnings deterioration. This provides a base for potential recovery, although current revenue contraction and renewed losses mean profitability remains unproven.

Improving Free Cash Flow TrendFree cash flow improved compared with the prior year, indicating some movement in the right direction for cash generation. The improvement is not yet durable support because operating and free cash flow remained negative in 2026, while the balance sheet is already stressed.

Bears Say

Sharp Revenue ContractionA near-50% annual revenue decline signals severe deterioration in demand, scale, or business execution and reduces visibility into future earnings. Sustained contraction can weaken operating leverage, constrain reinvestment, and make a durable return to profitability more difficult.

Negative Equity And High LeveragePersistently negative equity materially limits financial flexibility and indicates that liabilities exceed the recorded asset base. Debt remains substantial relative to assets, increasing balance-sheet vulnerability and restricting the company’s ability to fund operations or growth without additional support.

Persistent Losses And Weak MarginsLow gross margins combined with continuing operating and net losses indicate a structurally weak earnings model rather than a temporary profitability setback. Limited margin protection reduces the capacity to absorb revenue pressure, generate internal funding, or consistently improve financial resilience.

8156 FAQ

What was Sinopharm Tech Holdings Limited’s price range in the past 12 months?

Sinopharm Tech Holdings Limited lowest stock price was HK$0.06 and its highest was HK$0.36 in the past 12 months.

What is Sinopharm Tech Holdings Limited’s market cap?

Sinopharm Tech Holdings Limited’s market cap is HK$137.51M.

When is Sinopharm Tech Holdings Limited’s upcoming earnings report date?

Sinopharm Tech Holdings Limited’s upcoming earnings report date is Mar 04, 2027 which is in 154 days.

How were Sinopharm Tech Holdings Limited’s earnings last quarter?

Sinopharm Tech Holdings Limited released its earnings results on Sep 24, 2026. The company reported -HK$0.009 earnings per share for the quarter.

Is Sinopharm Tech Holdings Limited overvalued?

According to Wall Street analysts Sinopharm Tech Holdings Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sinopharm Tech Holdings Limited pay dividends?

Sinopharm Tech Holdings Limited does not currently pay dividends.

What is Sinopharm Tech Holdings Limited’s EPS estimate?

Sinopharm Tech Holdings Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sinopharm Tech Holdings Limited have?

Sinopharm Tech Holdings Limited has 633,693,050 shares outstanding.

What happened to Sinopharm Tech Holdings Limited’s price movement after its last earnings report?

Sinopharm Tech Holdings Limited reported an EPS of -HK$0.009 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Sinopharm Tech Holdings Limited?

Currently, no hedge funds are holding shares in HK:8156

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sinopharm Tech Holdings Limited

Sinopharm Tech Holdings Limited functions as an investment holding enterprise, with its primary focus on lottery operations across mainland China and Hong Kong. The company diversifies its activities into several key areas: it supplies both hardware and software systems for lottery services; develops and implements "Internet Plus" solutions for various industries including healthcare, government administration, property leasing, and public security; engages in the manufacturing and distribution of personal protective equipment; and offers additional services such as corporate management, supply chain optimization, data analytics, and online trading of goods. Founded in 1999 and headquartered in Sha Tin, Hong Kong, the company rebranded to Sinopharm Tech Holdings Limited in June 2019, having previously traded as China Vanguard You Champion Holdings Limited.